OBJECTIVES: Surgical ablation is a well-known treatment for atrial fibrillation (AF); however, little is known about the absolute success rate. The aim of this study is to compare the absolute pre-and postoperative incidence of AF after minimally invasive surgical ablation for paroxysmal AF.
INTRODUCTION
Minimally invasive surgical ablation is a well-known treatment for atrial fibrillation (AF); however, little is known about the absolute success rate of this treatment. In other studies, follow-up is incomplete, or there is no reliable comparison between pre-and postoperative AF burden.
The first surgical treatment for AF was performed in 1980 [1] . Since then, surgical techniques have developed, resulting in minimally invasive surgical ablation approaches for lone AF without the need of cardiopulmonary bypass. Since Haïssaguerre et al. demonstrated that paroxysmal AF (PAF) was mainly initiated by ectopic areas originating in the pulmonary veins (PVs), less complex ablation lesion sets are possible for patients suffering from PAF [2, 3] . Minimally invasive pulmonary vein isolation (MIPVI) has been a successful treatment for PAF since 2005 [4] [5] [6] . Boersma et al. [7] have shown that surgical ablation is superior to catheter ablation for patients with PAF in the FAST trial.
Unfortunately, it is difficult to determine the true results of the PVI, because the information provided by ECG or Holter is not a continuous registration. Postoperative follow-up nowadays usually consists of an ECG or 24-h Holter after a few months, which both are only small samples of the actual overall heart rhythm. According to the latest recommendations, several studies show continuous monitoring using a continuous loop monitor (CLM), implanted simultaneously during surgical PVI [8] [9] [10] . This is an excellent way to determine postoperative results; however, we believe that the preoperative AF burden is necessary in order to make an honest comparison using a CLM.
Our hypothesis is that comparison of the pre-and postoperative incidence of AF is the most unimpaired way to determine the results of MIPVI.
PATIENTS AND METHODS

Patient population
Between April 2010 and March 2011, 20 consecutive patients with ECG-proven AF were included to undergo a surgical bilateral, video-assisted, MIPVI, ganglionated plexi (GP) ablation, elimination of the ligament of Marshall and exclusion of the left atrial appendage (LAA) at the Department of Cardiothoracic Surgery in the Onze Lieve Vrouwe Gasthuis (OLVG) hospital in Amsterdam. Surgery was performed by a single surgeon. Two patients had undergone a percutaneous AF ablation prior to surgery. The patient characteristics are summarized in Table 1 .
Patients were presented for MIPVI by referring electrophysiologists (EPs) or by the EPs in our own centre. All patients were seen in the outpatient clinic by the performing surgeon, and asked for informed consent regarding the treatment. Before accepting them for MIPVI, all patients had to be free of structural heart disease. Therefore, all patients underwent transthoracic echocardiography and coronary artery analysis. Furthermore, computed tomography (CT) for visualization of the PVs and pulmonary function testing were also performed prior to surgery in all patients.
If there was no structural heart disease or anatomical problems, a CLM (Reveal XT®, Medtronic, Inc., Minneapolis, MN, USA) was implanted in patients 4 weeks prior to surgery in the outpatient clinic in order to perform home interrogations and transmissions. This procedure was done under local anaesthesia, optimally using a vector check. Patients transferred the data of the CLM through the CareLink® system weekly, and the data were evaluated in our hospital. The device continuously recorded the amount of AF per day [daily burden and the AF burden during the follow-up period, defined as the percentage of time in AF (AF%)]. If a weekly burden of more than 10% was present, surgery was planned 4 weeks later. If the burden was lower than 10% in 1 week, AADs were discontinued until the burden reached over 10%.
Surgical technique
Surgery was performed through a bilateral video-assisted minithoracotomy (fourth intercostal space) under general anaesthesia with a double-lumen endotracheal tube to facilitate single-lung ventilation with the patient lying on its left and right side, respectively. A transoesophageal echo was inserted to evaluate clots in the LAA prior to the incision and after that, retracted from the patient to prevent damage to the oesophagus during the ablation.
After opening the right thorax, the phrenic nerve was identified, and the pericardium on the right side was opened 2 cm above it. Blunt dissection of the oblique and transverse sinuses was performed. The Navigator® was inserted, and the PVs were encircled to later guide the Metronic Gemini S bipolar clamp. After encircling the PVs, the GPs were identified by focal electrical stimulation and, if present, immediately ablated with a Medtronic monopolar ablation pen. A decrease in R-R interval of more than 2.5 s was considered positive for the presence of GP. Then, the PVI was performed on the right side, using the Medtronic Gemini S with bipolar radiofrequency. Ablation was done 10 times in total on the PVs. Complete electrical isolation was confirmed by measurement of a bidirectional block by the pacemaker technician. If complete electrical isolation was not confirmed, bipolar ablation was repeated until a block was achieved. Then, a chest tube was inserted, and the wound was closed.
On the left side, the pericardium was opened 2 cm below the identified phrenic nerve. Marshall's ligament was cut, and the Navigator® was inserted in order to guide the Gemini S bipolar clamp. Again, the GPs were identified, and ablated immediately if present. After that, the PVI was performed on the left side. Then, the LAA was excluded by using a surgical stapling device (EndoGIA®, Covidien, Dublin, Ireland), and haemostasis was confirmed. A chest tube was inserted, and the wound was closed.
Postoperatively, all patients were transferred to the intensive care unit (ICU) for intensive monitoring because of the lack of a postoperative anaesthetic care unit (PACU) of medium care (MC) in our hospital. Most patients were extubated the evening of surgery. The next day, the chest tubes were removed, and the patients were transferred to the Cardiothoracic Ward. After 4-6 days, the patients were discharged. If patients were in sinus rhythm (SR), AADs were discontinued directly postoperatively.
Statistical methods
Results are reported as mean + standard deviation (SD), median (interquartile range, IQR) or as n (%). The pre-surgery AF burden was based on the average value recorded in the 4 weeks prior to surgery. Absolute reductions in AF burden from pre-surgery to blanking and follow-up periods are reported. Additionally, changes in AF burden were analysed with a paired t-test. All statistical analyses were performed using SAS software version 9.3 (SAS Institute, Cary, NC, USA). P-values of less than 0.05 were considered statistically significant.
Follow-up
In all patients, the CLM was cleared right after surgery. All patients transferred the data of the CLM weekly during the first 3 months after surgery, using the CareLink® system. Upon request, the patients could receive a text message or email in which the AF burden of that week was presented. One month after surgery, the patients were seen in the outpatient clinic for wound inspection. After 3 months, they were seen by their referring cardiologist. If the patients were in SR, for example, an AF burden of 0% after 3 months, AADs were discontinued, if not stopped before. Further follow-up was performed by patients' own cardiologist, while the patients transferred the data via the CareLink® system to our clinic monthly.
The primary endpoint of the study was to report the number of responders at 12 months using a CLM. A responder was defined as free of AF (by continuous monitoring) and free from antiarrhythmic medication. The 3-month post-surgery was considered a blanking period, and any recurrences of AF in this period were recorded but were not used for the 12-month outcome.
RESULTS
A total of 20 patients with the diagnosis of PAF had a CLM implanted between April 2010 and March 2011. During a median monitoring period of 34 days (IQR 33-34), 2 patients did not meet the threshold for surgical ablation. In the remaining 18 patients who underwent surgery, the average mean AF burden prior to surgery was 66% (Fig. 1 ). Four patients were on at least two AADs, and 2 patients had undergone a prior catheter ablation (Table 1) . Seventeen patients received a MIPVI and amputation of the LAA (LAAA). In 1 patient, surgery was discontinued because of a perioperative bleeding due to the adhesions caused by a prior ablation, before surgical ablation could be performed (Fig. 2) .
Post-procedure and at discharge
Postoperatively, 11 (65%) of 17 patients were in SR, and 6 (35%) remained in AF or showed episodes of AF before discharge. At discharge, these 6 (35%) patients were on AADs. In patients in SR, AADs were already discontinued at this stage. Discharge took place at an average of 5 days postoperatively.
Three months post-surgery (blanking period)
Within the first 3 months after surgery, there was a significant decrease in AF occurrences (Fig. 3) . During this blanking period, the mean decrease in burden was 53.7 ± 40.1%, P < 0.001. Ten (59%) patients had no AF recurrences during the blanking period. Again, AF recurrences during this blanking period were not used for the 12-month outcome. When patients were in SR after this blanking period, AADs were discontinued after visiting the cardiologist in the outpatient clinic.
Twelve months post-surgery
During the follow-up period, 13 patients did not have any recurrences of AF. The mean decrease in AF burden from pre-surgery to 12 months was 65 ± 43%, P < 0.001 (Fig. 3) .
At 12 months, 15 patients were in follow-up and 2 patients had their CLM removed. Of these 15 patients, 12 (80%) patients responded to therapy, and were free of AF and AADs after 12 months. One (6%) patient was free of AF but remained on AADs by own preference. Six (35%) patient reported rhythm irregularities during follow-up. Evaluation of these rhythm irregularities by our EP made clear that 4 of these 6 patients had no AF recurrence but SR with some premature ventricular complexes. None of these 4 patients in SR were on AADs at 12 months ( Table 2) . The other 2 patients (12%) did show AF, and AADs were resumed during follow-up (Table 3 ).
Complications of surgery
No patients died or suffered from major adverse cardiac or cerebral events. Two patients (12%) had the CLM explanted within 12 months after surgery, and could not contribute to the 12-month follow-up. The reason for explantation was a wound infection after a traumatic injury in 1 patient, and removal by the patient's own request in the other patient.
DISCUSSION
In this study, we showed an absolute reduction of AF burden of 65% after MIPVI or relative reduction of 100%. A total of 12 patients (80%) were proven to be responders at 12-month followup using a CLM. Several other studies already showed follow-up using a CLM [9, [11] [12] [13] [14] [15] 18] . This study differs from these studies because here, the CLM was implanted 4 weeks prior to surgery. In our opinion, this has some important advantages.
First of all, a comparison between pre-and postoperative burden can be made by implanting the device prior to surgery. The 4-week period is short; however, this was chosen for several reasons. By implanting the CLM 4 weeks prior to surgery, we were able to guarantee patients a maximum waiting period of 6 weeks from the moment they were seen in the outpatient clinic. Hence, our waiting list was almost non-existing. This also created an opportunity to operate on patients who were on a waiting list for percutaneous ablation. In the Netherlands and also in our hospital, this waiting list is very long, and varies from 3 to 12 months.
Of course, implanting the CLM longer before surgery gives more data, but it remains to be seen if this will add to determining the success rate of the operation, especially in patients with a high AF burden preoperatively.
Secondly, implanting the device prior to surgery gives an insight in the actual AF burden at that time. What we did not expect was to find patients who were referred to us for AF ablation but did not have any AF burden on the CLM prior to surgery. Stopping all AADs still did not show any AF in 2 of these patients and even now, over 4 years later, they are still in SR. This gives a unique opportunity to critically select patients for surgery. If the CLM had not been placed preoperatively, these patients would have undergone unnecessary surgery and hospital admission. So, implanting the CLM prior to surgery can help select the patient group more thoroughly. It is noteworthy that one of these patients underwent two electrocardioversions (ECVs) prior to referral to our department.
We found, with increasing experience over the last years, that in patients with a CLM implanted pre-surgery, the decision whether to perform a PVI or create a box lesion can be made more easily than in patients without a CLM. Patients with a mean high AF burden (above 40%) a week probably benefit more from a connecting box lesion than a PVI. At this moment, we are studying this hypothesis to see if these patients are indeed better off with a surgical technique that is adjusted to the preoperative AF burden. Also, this raises the question whether a surgical PVI should still be performed or if patients should undergo a percutaneous PVI and receive a surgical connecting box lesion if recurrence of AF is present. Since this is not the main topic of this study, we have chosen not to elaborate on this any further in this paper.
What also was of influence in selecting patients for surgery was having a cut-off burden of 10%. We have discussed this with our EPs before starting the programme. In our opinion, a burden of less than 10% a week means there is so little AF that the benefit of surgery does not compensate for the surgical risk. Also, it is questionable how much a patient suffers from AF that occurs rarely. This threshold implies that preoperative evaluation can be improved using a CLM. The CLM gives us a tool to optimize postoperative drug management. Patients who are under follow-up with a CLM are told to discontinue medication much sooner than those without CLM. The device gives us accurate information about the presence or absence of AF, and therefore provides a reliable way to decide whether or not patients should be on AADs and/or oral anticoagulants (OAC).
In terms of cost reduction, the use of a CLM for pre-and postoperative monitoring can be a valuable tool. Not only does it narrow down the criteria for surgery, as discussed above, drug management is also made easier by using the CLM as a follow-up tool. We have not yet made a cost-benefit analysis, but it is more than likely that all in all, using a CLM this way may provide a clear cost reduction. Since the majority of the normal population is likely to develop AF in the future, this is a very welcome benefit [16] .
Of course, there are some points of discussion using terms as 'responder' and 'non-responder'. For instance, some may find it easy to argue that a patient in AF but without symptoms may be referred to as a 'responder' to therapy. After all, for these physicians, the goal of the therapeutic treatment was to end up with an asymptomatic patient. However, our aim was to achieve continuous SR without use of AADs and if possible OAC. Herein lies one of the first limitations of the CLM. RR intervals are compared over a period of 2 min by the CLM. This implies that, very short periods of AF, shorter than 2 minutes, will not be recorded as arrhythmia by the CLM [12] . In some studies with CLM follow-up, atrial tachyarrhythmia lasting no longer than 30 s or even 2 min were not considered to be AF [11, 13, 15] . In our study, we consider every rhythm irregularity to be AF until proven otherwise by an EP. Moreover, in other studies, a responder is defined as AF burden of <0.5% [8, 14] . We defined a responder as a patient with 0% AF burden, without using AADs. If we would use a burden <0.5% as a definition for a responder, the success rate would automatically be higher; however, we chose not to. The aim of this study was not primarily to describe the success rate of the surgical procedure, but to establish whether a preoperatively implanted CLM would help us define the results of the procedure more and/or better than an ECG or Holter do at this moment.
Another point of discussion remains the possibility to discontinue OAC in patients who are proven to be free of AF by the CLM. In our opinion, this is a safe and valuable advantage of CLM follow-up. Since all patients have had their LAAA removed during surgery, the chance of thrombo-embolic complications for this patient group is not higher than in the normal population (given that the CHA2DS2 VASc score is normal). However, we are aware of the fact that a lot of cardiologists still believe that using a CLM as a follow-up tool is not validated yet and therefore, they will not use it as a guide to discontinue OAC.
In the results, it became clear that the patients with a high preoperative AF burden showed a higher recurrence rate than those with a lower preoperative AF burden. Although they were presented as PAF, it turned out that they were actually more towards persistent AF. In hindsight, these patients should have underwent a surgical connecting box lesion rather than a PVI [17] . Although these patients were not considered to be a 'responder', there was a remarkable reduction in AF burden in the first 12-month follow-up.
Since the beginning of this study, there have been developments in the way we handle this patient group. At this moment, we have a study population of at least 120 patients, and this number is still increasing. Furthermore, most patients nowadays receive a totally endoscopic MIPVI with a box lesion set, since most patients referred are in persistent AF. At the end of this procedure, the endotracheal tube is removed while the patient is still in theatre. Only a small number of patients is referred to us with true PAF. Here, the CLM again helps us to determine the best surgical treatment for the patient. Also, AADs are continued during the blanking period, whether the patient is in SR or not. They are discontinued if patients are in SR after 3 months, again, with weekly CLM follow-up during the blanking period.
In conclusion, even though this is only a small patient cohort, we believe that the use of a preoperatively implanted CLM benefits all patients treated for AF. It not only gives us the opportunity to optimize drug management postoperatively, but also provides very accurate information about the AF burden pre-surgery, allowing us to determine the best surgical procedure for each patient, thus enhancing patient selection. As an additional advantage, we found that it makes it even possible to withhold surgery in some patients who do not have any AF burden whatsoever, who otherwise would have been operated on, therefore adding to a beneficial cost reduction of the patient population.
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Dr M. Mariani (Groningen, The Netherlands): I have mainly one comment and two questions for you. The comment is, your paper gives new insight into the selection of AF patients for non-pharmacologic treatments, which is for me a great opportunity for all of us.
The first question is: After this successful initial experience of preoperative CLM, in which you have clearly demonstrated the value of an actual evaluation of the AF status with respect to the indication, have you changed your institutional practice or policy and decided to use the CLM for all AF patients scheduled for any type of non-pharmacological treatment of AF, which means, of course, either surgical or nonsurgical or transcatheter?
The second question is: You had the unique chance to look very carefully into the blanking period of AF patients after pulmonary vein isolation, which is one of my favourite topics, because I find that the blanking period is very much authority-based and very little evidence-based. So even if the number of patients in your study is small, do you think that the use of CLM may help identify the non-responders very early after the surgical treatment? In other words, have you seen a different pattern of AF burdens in non-responders compared to the responders during the blanking period?
Dr Oudeman: For your first question, since the beginning of this project, it's been our dream to realize this implantation of continuous loop monitoring and to give the patients the chance to show what they really have and to compare the different treatments between surgical ablation and cardiologic ablation. We are writing a study protocol to define the differences between cardiologists and our treatment, so this is something that will be revealed in the near future probably, hopefully, so we can analyse this very well. At this moment, we are not that far yet.
Regarding your second question, we expected to find the same things as you suggest, that the patients with recurrence did show AF in the blanking period, but it did not seem to be an effect. In the blanking period, 7 patients showed AF and 4 of these patients had undergone electro-cardioversion in this blanking period, during which 3 of them went to sinus rhythm, 1 patient converted to sinus rhythm after 2 months in the second months of the blanking period on medication, and 3 patients are left then. One of these patients continued to have some sort of AF during all 12 months. It was like a burden of 0.1%, 0.2%, until the eleventh month, and then it showed an increase in AF burden up to 2% and to 5% in the twelfth month. And the 2 other patients showed some paroxysmal atrial fibrillation in the blanking period, but it was over before the 3 months were completed. So in the fourth month, those patients were all in sinus rhythm. And there was one patient that developed AF in the eleventh month, but this patient was directly in sinus rhythm after the procedure and also during admission in hospital as well as in the complete blanking period.
Dr Mariani: I think that CLM really adds a valuable reliability to all studies, because you have heard several comments today and we always debate about the reliability of the follow-ups, and I think using these kinds of devices will be very useful to talk the same language, all of us.
Dr E. Charitos (Luebeck, Germany): First, you say that this strategy can improve patient selection. One could argue that in those patients who didn't have atrial fibrillation, the indication was false.
My question is: Why is 10% your cut-off? Why not 5%? Why not 20%? Do other factors play a role, such as symptoms, age or left atrium diameters?
Dr Oudeman: There is no literature known about this threshold cut-off point. We discussed it with our EPs in our hospital and we decided that, yes, if patients suffer from less than 10% of AF burden in time, how much do they suffer? It's discussable, definitely. But we decided to have this 10% AF cut-off point; because there is nothing in the literature, and we thought that the 10% is a reasonable cut-off point to compensate for the surgical risk and the benefit of surgery.
Dr Charitos: And other factors, other patient factors that you might want to consider?
Dr Oudeman: That is maybe something for the future, maybe after we know what the patient rhythm is pre-surgery in AF burden and recurrence, maybe we can look back in data and see what the left atrium diameter was or what the age was or what the duration of AF was. That's something that the future might bring us.
Dr N. Ad (Falls Church, VA, USA): So the Reveal XT is an exciting technology, but, as any other technology, has a lot of limitations. One is having a very high false-positive for AF specifically and very low sensitivity to other arrhythmias that are with a fixed R-R interval. So it all depends on the setting. So, I agree with the concept of scanning the patient, I think it's a very innovative approach.
I have some questions. How do you follow a patient? How do you download the data? Who is reviewing it? And what is the setting of the Reveal to basically minimize missing flutters?
Dr Oudeman: First of all, the information is sent to us by a CareLink system and rhythm irregularities are all checked out by our EP cardiologists. So they decide if it is atrial fibrillation or it's just a premature ventricle complex, so that makes a difference. And we know that an implantable Reveal is not a gold standard to evaluate the rhythm of patients, but it is able to say something about the rhythm.
